NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI shares have increased by 34.1% and is now trading at $55.72.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ChemoCentryx.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for ChemoCentryx.

ChemoCentryx Inc (NASDAQ:CCXI) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biopharmaceutical company had revenue of $6.01 million for the quarter, compared to the consensus estimate of $8.90 million. ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%.
View ChemoCentryx's earnings history.

9 analysts have issued twelve-month price targets for ChemoCentryx's shares. Their forecasts range from $54.00 to $102.00. On average, they anticipate ChemoCentryx's stock price to reach $69.78 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price.
View analysts' price targets for ChemoCentryx.

News coverage about CCXI stock has trended very positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ChemoCentryx earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about ChemoCentryx.

ChemoCentryx saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 4,960,000 shares, a drop of 6.1% from the July 15th total of 5,280,000 shares. Based on an average daily volume of 718,700 shares, the days-to-cover ratio is currently 6.9 days. Currently, 9.9% of the shares of the stock are sold short.
View ChemoCentryx's Short Interest.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Immunomedics (IMMU).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Arrowhead Pharmaceuticals (ARWR), Advanced Micro Devices (AMD), Opko Health (OPK), NVIDIA (NVDA) and Inovio Pharmaceuticals (INO).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by a number of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (0.65%), Emerald Mutual Fund Advisers Trust (0.59%), International Biotechnology Trust PLC (0.31%), UBS Group AG (0.23%), Swiss National Bank (0.15%) and Alps Advisors Inc. (0.14%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Alps Advisors Inc., WINTON GROUP Ltd, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, SG Americas Securities LLC, Trexquant Investment LP, and Genesee Capital Advisors LLC. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx.

CCXI stock was purchased by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Emerald Mutual Fund Advisers Trust, First Trust Advisors LP, Emerald Advisers LLC, Raymond James Financial Services Advisors Inc., Swiss National Bank, Russell Investments Group Ltd., and Rafferty Asset Management LLC.
View insider buying and selling activity for ChemoCentryx.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $55.72.

ChemoCentryx has a market capitalization of $3.45 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]